Recombinant human full-length ERG protein was used as the immunogen for the ERG antibody.
The transcription factor erythroblastosis virus E26 transforming sequence related gene (ERG) functions as a regulator of key cellular functions to promote endothelial homeostasis. Expression of ERG has been observed in both benign and malignant vascular endothelial tumors, such as hemangiomas and Kaposi sarcomas, respectively. Carcinomas of the breast, colon, and urothelium have demonstrated absence of ERG expression, whereas presence of the protein has been confirmed in a subset of prostate carcinoma cases. Anti-ERG can be a useful tool for identifying vascular endothelial neoplasms and distinguishing prostate carcinoma from epithelial tumors of non-prostatic origin.
